10-Q: SI-BONE Reports Q3 2024 Results, Revenue Up 19% Year-Over-Year

SI-BONE, Inc. announced its third-quarter 2024 financial results, highlighting a 19% increase in revenue compared to the same period last year.

Summary

• SI-BONE, Inc. reported a net loss of $6.575 million for the third quarter of 2024, an improvement from the $10.022 million loss in the same quarter of 2023.
• Revenue for the quarter reached $40.340 million, a 19% increase from $34.014 million in Q3 2023, driven by increased case volumes in the U.S. and internationally.
• Gross profit for the quarter was $31.903 million, up from $26.973 million in the prior year, with a consistent gross margin of 79%.
• Operating expenses totaled $39.536 million, compared to $38.142 million in Q3 2023, with increases in sales and marketing, research and development, and general and administrative costs.
• For the nine months ended September 30, 2024, the company's net loss was $26.418 million, compared to $32.353 million for the same period in 2023.
• Year-to-date revenue was $118.176 million, an 18% increase from $100.027 million in the first nine months of 2023.
• The company's cash and marketable securities totaled $150.8 million as of September 30, 2024, down from $166.0 million at the end of 2023.
• SI-BONE has a term loan of $36.2 million outstanding as of September 30, 2024, and has refinanced this loan in November 2024, extending the maturity date to September 1, 2029.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and improving losses, but also highlights risks and challenges that temper the overall sentiment. The company is showing progress but still has work to do to achieve profitability.

Positives

• The company experienced a significant increase in revenue, indicating strong market demand for its products.
• The company's gross margin remained stable, suggesting efficient cost management.
• The net loss decreased compared to the same period last year, showing progress towards profitability.
• The company has expanded its sales force and physician training programs, which should support future growth.
• The company has a strong presence in ambulatory surgery centers, a growing market segment.

Negatives

• The company continues to operate at a net loss, indicating ongoing challenges to achieve profitability.
• Operating expenses increased, which could impact future profitability if not managed effectively.
• The company's cash and marketable securities decreased, which may require future capital raises.

Risks

• The company is subject to a civil investigative demand from the U.S. Department of Justice, which could have a material impact on its business.
• The company relies on a limited number of suppliers, which may impact the availability of instruments and materials.
• The company's business is subject to seasonal variations, which may impact revenue.
• The company's ability to access credit on favorable terms may be limited due to changes in credit markets.
• The company is subject to various healthcare fraud and abuse laws, and failure to comply could negatively affect its business.

Future Outlook

The company believes that its existing cash and marketable securities will enable it to fund its operating expenses and capital expenditure requirements over the next 12 months. The company anticipates the results for the primary endpoint in 2025 for the SILVIA study and anticipates publishing follow-up results in 2025 for the SAFFRON study.

Management Comments

• The company is focused on increasing its sales managers' capacity and driving sales force productivity.
• The company is working closely with its suppliers to reduce lead time for its implants.
• The company is integrating its demand planning and manufacturing systems to leverage actual usage trends.

Industry Context

The company operates in the medical device industry, specifically focusing on musculoskeletal disorders of the sacropelvic anatomy. The company's growth is influenced by the increasing adoption of minimally invasive surgical procedures and the growing number of procedures being performed at ambulatory surgery centers. The company's focus on clinical evidence and physician engagement is aligned with industry trends.

Comparison to Industry Standards

• SI-BONE's revenue growth of 19% in Q3 2024 is strong compared to the average growth rate of the medical device industry, which is typically in the single-digit range.
• The company's gross margin of 79% is within the typical range for medical device companies, but may be lower than some companies with higher-priced products.
• The company's net loss, while improving, is still a concern compared to more established and profitable medical device companies.
• The company's focus on minimally invasive procedures and ASCs aligns with industry trends, but its success will depend on its ability to compete with larger players in the market.
• Compared to companies like Globus Medical and NuVasive, which also focus on spinal and orthopedic solutions, SI-BONE is smaller but has a more focused product portfolio.

Legal Proceedings

• In October 2024, the company received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.

Related Party Transactions

• The company had a joint development agreement with SeaSpine Orthopedics Corporation, which merged with Orthofix Medical, Inc. The company did not incur any reimbursement charges from Seaspine for the three and nine months ended September 30, 2023.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and improving losses, but concerned about the ongoing net loss and potential legal issues.
• Employees may benefit from the company's growth and investment in talent, but may be concerned about the potential impact of the legal investigation.
• Customers may benefit from the company's expanding product portfolio and physician training programs.
• Suppliers may benefit from the company's growth, but may be impacted by supply chain disruptions.
• Creditors may be concerned about the company's ongoing net loss and potential legal issues, but may be encouraged by the revenue growth and refinancing of the term loan.

Next Steps

• The company will continue to selectively expand its sales force.
• The company will continue to engage and educate physicians and other healthcare professionals about the clinical merits and patient benefits of its solutions.
• The company will continue to invest in research and development initiatives to bring new and differentiated solutions to the market.
• The company will continue to evolve its business processes to identify, measure and improve operational efficiency.

Key Dates

Keywords

SI-BONE, sacroiliac joint dysfunction, medical devices, spinal fusion, pelvic fixation, iFuse, orthopedic implants, surgical procedures, healthcare, revenue growth